Global Clinical Trials Support Services Market Forecast 2022-2030

The global clinical trials support services market is estimated to boost with a 7.65% CAGR during the assessment period, 2022-2030. The market growth is driven by the rising prevalence of chronic disease & virus outbreaks and various benefits of clinical trial support services.

MARKET INSIGHTS

Clinical trials are controlled studies on humans to ensure the efficacy of drugs, food, and other product. These clinical trials are designed to satisfy the requirements of an agency related to product approvals and other human studies used in developing a product. Experiments and tests are performed on people and animals, and later the researchers or the investigators examine the outcomes

Further, support services make the clinical trial process easier. There are various key drivers for the growth of the studied market: the rise in the number of diseases and overcoming the challenges in clinical trials. The rising health problems and diseases have increased the clinical trials of new vaccines for new viruses and new and efficient drugs for the existing problems.

REGIONAL INSIGHTS

The global clinical trials support services market growth evaluation includes a thorough analysis of Europe, North America, Asia-Pacific, and Rest of World. North America is expected to capture around 38.27% market share by 2030 due to the presence of numerous leading industry players and advanced clinical studies in the region.

COMPETITIVE INSIGHTS

The competition is very high among the companies since the global clinical trials support services market is consolidated. Also, there are entry barriers for new entrants because of the presence of influential market leaders.

Some of the key market players include: ICON PLC, IQVIA, Parexel, PSI CRO, KCR, etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation caters to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 47763

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. RISING PREVALENCE OF CHRONIC DISEASE & VIRUS OUTBREAKS
- 3.1.2. BENEFITS OF CLINICAL TRIAL SUPPORT SERVICES
3.2. KEY RESTRAINTS
- 3.2.1. AVAILABILITY OF OPEN-SOURCE/FREEWARE SOFTWARE
- 3.2.2. STRINGENT REGULATIONS

4. KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON CLINICAL TRIALS SUPPORT SERVICES MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. VALUE CHAIN ANALYSIS
4.7. KEY BUYING CRITERIA
- 4.7.1. PERFORMANCE
- 4.7.2. EASE OF USE
- 4.7.3. SECURITY
- 4.7.4. COST-EFFECTIVENESS
4.8. REGULATORY FRAMEWORK

5. MARKET BY PHASE

5.1. PHASE I
5.2. PHASE II
5.3. PHASE III
5.4. PHASE IV

6. MARKET BY SPONSOR

6.1. PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
6.2. MEDICAL DEVICE COMPANIES
6.3. OTHER SPONSORS

7. MARKET BY SERVICE

7.1. CLINICAL TRIAL SITE MANAGEMENT
7.2. ADMINISTRATIVE STAFF
7.3. PATIENT RECRUITMENT MANAGEMENT
- 7.3.1. PATIENT RECRUITMENT & REGISTRY SERVICES
- 7.3.2. PATIENT RETENTION
- 7.3.3. OTHER PATIENT RECRUITMENT MANAGEMENT
7.4. IRB
7.5. DATA MANAGEMENT
7.6. OTHER SERVICES

8. GEOGRAPHICAL ANALYSIS

8.1. NORTH AMERICA
- 8.1.1. MARKET SIZE & ESTIMATES
- 8.1.2. KEY GROWTH ENABLERS
- 8.1.3. KEY CHALLENGES
- 8.1.4. KEY PLAYERS
- 8.1.5. COUNTRY ANALYSIS
  - 8.1.5.1. UNITED STATES
  - 8.1.5.2. CANADA
8.2. EUROPE
- 8.2.1. MARKET SIZE & ESTIMATES
- 8.2.2. KEY GROWTH ENABLERS
- 8.2.3. KEY CHALLENGES
- 8.2.4. KEY PLAYERS
- 8.2.5. COUNTRY ANALYSIS
  - 8.2.5.1. UNITED KINGDOM
  - 8.2.5.2. GERMANY
  - 8.2.5.3. FRANCE
  - 8.2.5.4. SPAIN
  - 8.2.5.5. ITALY
  - 8.2.5.6. SWEDEN
  - 8.2.5.7. DENMARK
  - 8.2.5.8. HUNGARY
  - 8.2.5.9. REST OF EUROPE
8.3. ASIA-PACIFIC
- 8.3.1. MARKET SIZE & ESTIMATES
- 8.3.2. KEY GROWTH ENABLERS
- 8.3.3. KEY CHALLENGES
- 8.3.4. KEY PLAYERS
- 8.3.5. COUNTRY ANALYSIS
  - 8.3.5.1. CHINA
  - 8.3.5.2. JAPAN
  - 8.3.5.3. INDIA
  - 8.3.5.4. SOUTH KOREA
  - 8.3.5.5. TAIWAN
  - 8.3.5.6. SINGAPORE
  - 8.3.5.7. THAILAND
  - 8.3.5.8. AUSTRALIA & NEW ZEALAND
  - 8.3.5.9. REST OF ASIA-PACIFIC
8.4. REST OF WORLD
- 8.4.1. MARKET SIZE & ESTIMATES
- 8.4.2. KEY GROWTH ENABLERS
- 8.4.3. KEY CHALLENGES
- 8.4.4. KEY PLAYERS
- 8.4.5. COUNTRY ANALYSIS
  - 8.4.5.1. LATIN AMERICA
  - 8.4.5.2. MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

9.1. KEY STRATEGIC DEVELOPMENTS
- 9.1.1. MERGERS & ACQUISITIONS
- 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 9.1.3. PARTNERSHIPS & AGREEMENTS
- 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
- 9.2.1. ADVANCED CLINICAL
- 9.2.2. ALCURA
- 9.2.3. CHARLES RIVER LABORATORIES INC
- 9.2.4. CLINIPACE
- 9.2.5. CTI CLINICAL TRIAL AND CONSULTING SERVICES INC
- 9.2.6. ICON PLC
- 9.2.7. IQVIA
- 9.2.8. KCR
- 9.2.9. LABCORP DRUG DEVELOPMENT
- 9.2.10. MEDPACE
- 9.2.11. PAREXEL
- 9.2.12. PSI CRO
- 9.2.13. SYNEOS HEALTH
- 9.2.14. WORLDWIDE CLINICAL TRIALS
- 9.2.15. WUXI APPTEC